Integra LifeSciences (NASDAQ:IART) Reaches New 12-Month Low Following Analyst Downgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART) reached a new 52-week low during mid-day trading on Thursday after Citigroup lowered their price target on the stock from $11.00 to $9.00. Citigroup currently has a sell rating on the stock. Integra LifeSciences traded as low as $8.91 and last traded at $8.9750, with a volume of 301019 shares. The stock had previously closed at $9.61.

A number of other research analysts have also weighed in on IART. Wells Fargo & Company cut their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, February 27th. Wall Street Zen downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $14.40.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Corient Private Wealth LLC bought a new stake in shares of Integra LifeSciences in the fourth quarter valued at about $189,000. Virtu Financial LLC bought a new position in Integra LifeSciences during the fourth quarter valued at about $124,000. Invesco Ltd. raised its holdings in Integra LifeSciences by 0.9% in the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after acquiring an additional 31,931 shares in the last quarter. State of Tennessee Department of Treasury raised its holdings in Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after acquiring an additional 1,964 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Integra LifeSciences by 2.4% in the 4th quarter. Wellington Management Group LLP now owns 1,353,467 shares of the life sciences company’s stock worth $16,810,000 after acquiring an additional 32,192 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

The company has a market cap of $714.71 million, a price-to-earnings ratio of -1.36 and a beta of 1.02. The company has a fifty day moving average price of $11.47 and a two-hundred day moving average price of $12.93. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.04. The business had revenue of $434.93 million during the quarter, compared to analyst estimates of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.Integra LifeSciences’s revenue was down 1.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.